Expert view: High viscosity, high volume biologics call for new delivery device designs

Posted: 23 October 2020 | | No comments yet

The increasing use of subcutaneous administration stems from the significant advances in biological drug development, as well as the rising trend of self-administration.

Further driving this movement is the growing number of biologics patents reaching expiry, thereby allowing the development of more affordable biosimilars. As intravenous drugs continue to be reformulated for subcutaneous administration, there is a growing need for safe and effective drug delivery device designs that can cope with the larger dose volumes and higher viscosity formulations typical of these drugs.

    To read this expert view in full, please complete the form below:


    This specialist content is provided to you free-of-charge thanks to the kind support of Owen Mumford

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.